Fernando Cotait Maluf
Hospital Beneficência Portuguesa de São Paulo and Hospital Israelita Albert Einstein · Hospital Israelita Albert Einstein · Latin American Cooperative Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fernando Cotait Maluf as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07815197 · Sacituzumab Tirumotecan as Second-Line Treatment for Penile CancerLatin American Cooperative Oncology Group · not yet recruiting · Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma · principal investigator
- Ph2NCT07808359 · Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell CarcinomaLatin American Cooperative Oncology Group · not yet recruiting · Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma · principal investigator
- Ph2NCT07804966 · Sac-TMT in Vaginal and Vulvar CancersLatin American Cooperative Oncology Group · not yet recruiting · Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma · principal investigator
- Ph2NCT06527690 · Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate CancerLatin American Cooperative Oncology Group · withdrawn · Prostate Cancer, Castrate Resistant Prostate Cancer, Homologous Recombination Deficiency · principal investigator
- N/ANCT04962919 · Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.Latin American Cooperative Oncology Group · completed · Prostatic Neoplasms, Castration-Resistant · principal investigator
- Ph2NCT04224740 · Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile CancerLatin American Cooperative Oncology Group · completed · Penile Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:02 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.N Engl J Med · 2024164 citationsRCR 24.0
- 34 citationsRCR 0.8
- Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.Int J Gynecol Cancer · 200626 citationsRCR 0.7
- A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.Gynecol Oncol · 201518 citationsRCR 0.7
- A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.Int J Gynecol Cancer · 200713 citationsRCR 0.3
- 13 citationsRCR 0.4
- Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma.Cancer · 20099 citationsRCR 0.2
- Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open · 20254 citationsRCR 1.1
- Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.Clin Genitourin Cancer · 20212 citationsRCR 0.2